AU Patent

AU2020250195B2 — Rapamycin Powders for Pulmonary Delivery

Assigned to Merz Pharmaceuticals LLC · Expires 2022-06-02 · 4y expired

What this patent protects

The invention provides stable, spray- dried, particle formulations containing rapamycin, or pharmaceutically acceptable salts of rapamycin, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.

USPTO Abstract

The invention provides stable, spray- dried, particle formulations containing rapamycin, or pharmaceutically acceptable salts of rapamycin, which are useful for pulmonary administration to the respiratory tract of a patient for the treatment of disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020250195B2
Jurisdiction
AU
Classification
—
Expires
2022-06-02
Drug substance claim
No
Drug product claim
No
Assignee
Merz Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.